Chromogenic in situ hybridization analysis of HER‐2/neu status in cytological samples of breast carcinoma
Authors:
- 13 December 2004
- journal article
- Published by Wiley in Cytopathology
- Vol. 15 (6) , 315-320
Abstract
The current use of humanized monoclonal antibody trastuzumab for the treatment of patients with metastatic breast cancer has made evaluation of HER-2/neu status an important clinical issue. Chromogenic in situ hybridization (CISH), in which the DNA probe is detected with an immunohistochemistry (IHC)-like peroxidase reaction, has been recently developed for the assessment of HER-2/neu status in formalin-fixed breast cancer specimens. We have applied the technique of dual-colour CISH using HER-2/neu and chromosome 17 centromere probes in 27 cytological smears, and these cytological samples were obtained from scrapings of fresh breast tumours. We also investigated HER-2/neu amplification and protein overexpression in the corresponding surgical tissues by CISH and IHC using the monoclonal antibody CB11. Of the 27 cytological cases, HER-2/neu gene amplification was observed in nine cases that were positive cases (2+ and 3+) for IHC. Among the 13 IHC positive cases (2+ and 3+), four of them showed no gene amplification. Identical results for the CISH technique were obtained in the matched surgical samples. The scrape samples from fresh breast tumour offer a monolayer cell population that is especially suitable for CISH. This study has shown that the cytological smear might be a good alternative for the CISH test.Keywords
This publication has 24 references indexed in Scilit:
- Best Practice No 176Journal of Clinical Pathology, 2004
- HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinomaCancer, 2003
- Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast CancerAmerican Journal of Clinical Pathology, 2003
- Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast CarcinomaLaboratory Investigation, 2002
- Current Status of HER2 TestingAmerican Journal of Clinical Pathology, 2001
- Chromogenic in Situ HybridizationThe American Journal of Pathology, 2000
- Subtracted, Unique-Sequence, In Situ HybridizationThe American Journal of Pathology, 1998
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase ActivityScience, 1986